3-methylcytosine profile

3-methylcytosine : A pyrimidone that is cytosine in which the hydrogen attached to the nitrogen at position 3 is substituted by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	140523
CHEBI ID	39992
SCHEMBL ID	102725
SCHEMBL ID	21917363
MeSH ID	M0110894

Synonym
2(1h)-pyrimidinone, 4-imino-3-methyl-
19380-02-0
2(1h)-pyrimidinone,4-imino-3-methyl-
3MCT
3-methylcytosine
3MC ,
AKOS006347212
6-amino-1-methylpyrimidin-2-one
2(1h)-pyrimidinone, 6-amino-1-methyl-
4776-08-3
6-amino-1-methylpyrimidin-2(1h)-one
CHEBI:39992
SCHEMBL102725
6-amino-1-methyl-2(1h)-pyrimidinone
6-amino-1-methyl-1,2-dihydropyrimidin-2-one
3-methyl-(7ci,8ci)-cytosine, 3-methylcytosine
SCHEMBL21917363
DTXSID80941068
Q15632786
BS-47175
DTXSID80901521
noname_648
F76096

Role	Description
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pyrimidone	A pyrimidine carrying one or more oxo substituents.
aminopyrimidine	A member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
methylcytosine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, VP39	Vaccinia virus	Kd	85.5000	85.5000	114.7500	144.0000	AID977611
Chain A, VP39	Vaccinia virus	Kd	85.5000	85.5000	114.7500	144.0000	AID977611
Chain A, VP39	Vaccinia virus	Kd	85.5000	85.5000	114.7500	144.0000	AID977611
Chain A, VP39	Vaccinia virus	Kd	85.5000	85.5000	114.7500	144.0000	AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Assay ID	Title	Year	Journal	Article
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	1999	Proceedings of the National Academy of Sciences of the United States of America, Jun-22, Volume: 96, Issue:13	mRNA cap recognition: dominant role of enhanced stacking interactions between methylated bases and protein aromatic side chains.
AID1811	Experimentally measured binding affinity data derived from PDB	1999	Proceedings of the National Academy of Sciences of the United States of America, Jun-22, Volume: 96, Issue:13	mRNA cap recognition: dominant role of enhanced stacking interactions between methylated bases and protein aromatic side chains.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (13.64)	18.7374
1990's	1 (4.55)	18.2507
2000's	9 (40.91)	29.6817
2010's	4 (18.18)	24.3611
2020's	5 (22.73)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (8.70%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	21 (91.30%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	5.33	10	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytosine [no description available]	6.04	21	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	2.01	1	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
thymine [no description available]	2.44	2	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
methyl methanesulfonate [no description available]	2.05	1	methanesulfonate ester	alkylating agent; apoptosis inducer; carcinogenic agent; genotoxin; mutagen
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	2.01	1	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
dimethylnitrosamine Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.	1.96	1	nitrosamine	geroprotector; mutagen
methanesulfonic acid [no description available]	2.31	1	alkanesulfonic acid; one-carbon compound	Escherichia coli metabolite
methylnitrosourea Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.	2.37	2	N-nitrosoureas	alkylating agent; carcinogenic agent; mutagen; teratogenic agent
1-methyladenosine [no description available]	7.31	1	methyladenosine	human metabolite
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	7.31	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
1-methylcytosine 1-methylcytosine: RN given refers to parent cpd. 1-methylcytosine : A pyrimidone that is cytosine in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group.	2	1	aminopyrimidine; methylcytosine; pyrimidone	metabolite
1-methylguanosine 1-methylguanosine : Guanosine substituted with a methyl group at position N-1.	2.05	1	methylguanosine	metabolite
3-methylthymine 3,5-dimethyluracil : A pyrimidone that is uracil with methyl group substituents at positions 3 and 5.	2.44	2	methylthymine; pyrimidone	metabolite
anticodon Anticodon: The sequential set of three nucleotides in TRANSFER RNA that interacts with its complement in MESSENGER RNA, the CODON, during translation in the ribosome.	2.41	1
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	2.52	2	guanosines; purines D-ribonucleoside	fundamental metabolite
1-methyladenine 1-methyladenine : Adenine substituted with a methyl group at position N-1.	5.24	9
3-methyladenine N3-methyladenine: structure in first source	1.96	1
methylnitronitrosoguanidine Methylnitronitrosoguanidine: A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties.. N-methyl-N'-nitro-N-nitrosoguanidine : An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position	1.96	1	nitroso compound	alkylating agent
7-methylguanosine 7-methylguanosine : A positively charged methylguanosine in which a single methyl substituent is located at position 7.	2.31	1	methylguanosine; organic cation	metabolite

Condition	Relationship Strength	Studies
Aura [description not available]	2.25	1
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	2.25	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.31	1
Benign Neoplasms [description not available]	2.13	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.13	1
Cancer of Pancreas [description not available]	2.15	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.15	1

3-methylcytosine

Description

Cross-References

Synonyms (23)

Roles (1)

Drug Classes (3)

Protein Targets (4)

Activation Measurements

Bioassays (2)

Research

Studies (22)

Market Indicators

Research Demand Index: 21.58

Study Types